Leap Therapeutics, Inc.

( )
LPTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -3.21%137.710.0%$882.45m
AMGNAmgen, Inc. -0.57%243.961.5%$790.47m
GILDGilead Sciences, Inc. 0.06%63.221.0%$521.54m
VRTXVertex Pharmaceuticals, Inc. -3.62%252.351.9%$443.84m
REGNRegeneron Pharmaceuticals, Inc. -1.25%659.202.6%$405.47m
NVAXNovavax, Inc. 0.31%52.1175.7%$298.25m
ILMNIllumina, Inc. -1.40%239.813.3%$290.13m
BIIBBiogen, Inc. -3.54%195.711.8%$236.80m
BNTXBioNTech SE -1.72%157.060.0%$216.85m
SNSSSunesis Pharmaceuticals, Inc. -2.86%2.040.7%$142.60m
EXASEXACT Sciences Corp. -3.90%52.0017.7%$137.77m
NKTXNkarta, Inc. -5.29%13.080.0%$101.27m
BMRNBioMarin Pharmaceutical, Inc. -1.19%78.184.2%$97.95m
TECHBio-Techne Corp. -3.22%359.094.5%$96.25m
TXG10X Genomics, Inc. -4.31%47.330.0%$90.40m

Company Profile

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.